OxyContin maker says it will no longer market opioid to doctors

Within a surprise reversal, the maker from the powerful painkiller OxyContin said Sunday that it will stop promoting opioid medications to doctors.

Manufacturer Purdue bowed to a key demand of legal cases that blame the Connecticut-based firm for helping trigger the opioid epidemic.

The company’s statement said it removed more than half its sales staff immediately and will no longer send sales associates to doctors’ offices to discuss opioid drugs.

Its remaining sales staff of approximately 200 will focus on other medicines.

Doctor Andrew Kolodny, director of opioid policy research at Brandeis University or college and an advocate for more powerful regulation of opioid drug businesses.

The creator of the powerful painkiller OxyContin stated Saturday that it will stop promoting opioid drugs to doctors.   (AP)

“The einstein (umgangssprachlich) is already out of the bottle, ” Kolodny said. “Millions of Americans are actually opioid-addicted because the campaign that Purdue and other opioid manufacturers used to enhance prescribing worked well. ”

He mentioned Purdue’s decision is helpful, but it refuse to make a major difference unless some other opioid drug companies do the exact same.


“We would have more success in motivating cautious prescribing if drug businesses stopped promoting aggressive prescribing, inch he told the Times.

Oughout. S. deaths linked to opioids have got quadrupled since 2000 to approximately 42, 000 in 2016, or even about 115 lives lost daily. More than 7 million Americans are usually estimated to have abused OxyContin considering that its 1996 debut, the La Times reported.

The report said claims where OxyContin abuse rates had been the highest “experienced the largest increases within heroin deaths, ” a research through Penn’ s Wharton School plus Rand said.

OxyContin has long been the tour’s top-selling opioid painkiller, bringing in great in sales for the privately-held corporation.


Eventually, Purdue acknowledged that will its promotions exaggerated the drug’s safety and minimized the risks associated with addiction.

“They are still doing this abroad, inch Kolodny said of their international equip Mundipharma. “They are following the exact same playbook that they used in the United States. inch

Purdue and other opioid drugmakers and pharmaceutical distributors keep on defending themselves against hundreds of nearby and state lawsuits seeking to keep the industry accountable for the drug overdose epidemic.

The Associated Press led to this report.